CN116019768A - 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 - Google Patents

靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 Download PDF

Info

Publication number
CN116019768A
CN116019768A CN202310169465.9A CN202310169465A CN116019768A CN 116019768 A CN116019768 A CN 116019768A CN 202310169465 A CN202310169465 A CN 202310169465A CN 116019768 A CN116019768 A CN 116019768A
Authority
CN
China
Prior art keywords
sbt
dha
oil
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310169465.9A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·E·伊根
伊瓦奥·奥吉马
曼苏尔·M·阿米吉
加林娜·伊凡诺夫娜·伯奇基娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Research Foundation of the State University of New York
Original Assignee
Targagenix Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Research Foundation of the State University of New York filed Critical Targagenix Inc
Publication of CN116019768A publication Critical patent/CN116019768A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310169465.9A 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 Pending CN116019768A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
US62/346,755 2016-06-07
CN201780047015.5A CN109562065A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780047015.5A Division CN109562065A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN116019768A true CN116019768A (zh) 2023-04-28

Family

ID=60578981

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310169465.9A Pending CN116019768A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN201780047015.5A Pending CN109562065A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780047015.5A Pending CN109562065A (zh) 2016-06-07 2017-06-07 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法

Country Status (9)

Country Link
US (3) US10206875B2 (enExample)
EP (1) EP3463299A4 (enExample)
JP (1) JP7518604B2 (enExample)
CN (2) CN116019768A (enExample)
AU (1) AU2017277497B2 (enExample)
CA (1) CA3026412A1 (enExample)
IL (1) IL263504A (enExample)
MX (1) MX2018015112A (enExample)
WO (1) WO2017214260A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体
CN114599394A (zh) * 2019-10-25 2022-06-07 安进公司 用于在低蛋白浓度下使蛋白损失最小化的组合物和方法
CA3157484A1 (en) * 2019-11-05 2021-05-14 Ulagaraj Selvaraj Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901901A (zh) * 2003-10-30 2007-01-24 纽约州州立大学研究基金会 紫杉醇－脂肪酸结合物及其药物组合物
CN101094646A (zh) * 2004-09-28 2007-12-26 陈献 用于输送紫杉烷及其它不溶性药物的低油乳剂组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
EP2317978A2 (en) * 2008-07-23 2011-05-11 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
US11197828B2 (en) * 2014-06-19 2021-12-14 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
JP6634034B2 (ja) * 2014-06-25 2020-01-22 シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドＳｙｎｅｒｇｉａ Ｂｉｏ Ｓｃｉｅｎｃｅｓ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 医薬水中油型ナノエマルジョン
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901901A (zh) * 2003-10-30 2007-01-24 纽约州州立大学研究基金会 紫杉醇－脂肪酸结合物及其药物组合物
CN101094646A (zh) * 2004-09-28 2007-12-26 陈献 用于输送紫杉烷及其它不溶性药物的低油乳剂组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘蜀宝主编: "《药剂学》", 31 July 2007, 河南科学技术出版社, pages: 488 *

Also Published As

Publication number Publication date
EP3463299A1 (en) 2019-04-10
AU2017277497B2 (en) 2023-05-04
WO2017214260A1 (en) 2017-12-14
CN109562065A (zh) 2019-04-02
JP7518604B2 (ja) 2024-07-18
MX2018015112A (es) 2019-09-09
US20180028442A1 (en) 2018-02-01
CA3026412A1 (en) 2017-12-14
AU2017277497A1 (en) 2018-12-20
NZ748915A (en) 2024-09-27
JP2019523226A (ja) 2019-08-22
US10206875B2 (en) 2019-02-19
EP3463299A4 (en) 2020-01-15
USRE50096E1 (en) 2024-08-27
US20250009658A1 (en) 2025-01-09
IL263504A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
USRE50096E1 (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
Ahmad et al. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth
Liu et al. The effect of triptolide‐loaded exosomes on the proliferation and apoptosis of human ovarian cancer SKOV3 cells
El-Readi et al. Cancer nanomedicine: a new era of successful targeted therapy
Zhang et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy
Pachauri et al. Piperine loaded PEG-PLGA nanoparticles: Preparation, characterization and targeted delivery for adjuvant breast cancer chemotherapy
Chiang et al. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds
Yi et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers
Wang et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery
Di-Wen et al. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers
Sabzichi et al. Fabrication of all-trans-retinoic acid-loaded biocompatible precirol: A strategy for escaping dose-dependent side effects of doxorubicin
Kim et al. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
Algandaby et al. Augmentation of anti-proliferative, pro-apoptotic and oxidant profiles induced by piceatannol in human breast carcinoma MCF-7 cells using zein nanostructures
Raikwar et al. Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape
Pavan et al. Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Badparvar et al. pH/redox responsive size‐switchable intelligent nanovehicle for tumor microenvironment targeted DOX release
Wohlfart et al. Treatment of glioblastoma with poly (isohexyl cyanoacrylate) nanoparticles
Kommineni et al. Stealth liposomal chemotherapeutic agent for triple negative breast cancer with improved pharmacokinetics
Gupta et al. Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin
Rajendra et al. Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
Myat et al. Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells
Chavoshi et al. Crocin-loaded liposomes sensitize MDA-MB 231 breast cancer cells to doxorubicin by inducing apoptosis
Wen et al. Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination